Request availability and a quotation for your required quantity and destination.
| Product | Liraglutide 6 mg/mL - Victoza Pen |
|---|---|
| Categories | Weight Loss |
| Availability | Confirmed on enquiry |
Product listing is not a recommendation to use this medicine. Prescription and destination requirements apply where relevant.
Active ingredient: Liraglutide
Listed strength: 6 mg/mL
Form: Subcutaneous injection pen
Class: GLP-1 receptor agonist
Supply: Prescription and destination-country regulations apply
Victoza is a once-daily liraglutide injectable for type 2 diabetes. The 6 mg/mL figure describes the solution concentration, not a single administered dose. Product-specific indications and age limits differ internationally; verify the leaflet and the exact pen presentation before use.
Victoza is prescribed to improve glycaemic management in eligible patients with type 2 diabetes. The U.S. label also includes certain cardiovascular-risk reduction uses in adults with type 2 diabetes and established cardiovascular disease. It should not be marketed as an interchangeable substitute for a separately approved weight-loss treatment.
Liraglutide activates GLP-1 receptors, influencing glucose-dependent insulin secretion, glucagon release and gastric emptying. Appetite effects can occur. This does not mean every person will experience the same glycaemic or weight response.
This liraglutide pen is generally injected once daily. Only follow the dose schedule and injection instructions provided by the prescriber and manufacturer. Subcutaneous sites include abdomen, thigh or upper arm depending on the product leaflet. Do not share pens, even if needles are changed. Do not alter the strength, reuse needles or combine GLP-1 medicines without professional guidance. Discuss storage and temperature-control requirements before international supply.
GLP-1 treatments carry clinically significant warnings. U.S. labeling includes a boxed thyroid C-cell tumor warning and contraindicates use with personal or family history of medullary thyroid carcinoma or MEN2. A previous serious allergic reaction to the active ingredient is also a contraindication. Discuss pregnancy, planned surgery requiring anaesthesia or deep sedation, pancreas or gallbladder disease, kidney problems, severe gastrointestinal effects and all concurrent medicines with the clinician.
Potential adverse effects include nausea, vomiting, diarrhoea, constipation and abdominal discomfort. Dehydration can contribute to kidney injury; hypoglycaemia may be more likely with insulin or sulfonylureas. Seek prompt medical care for persistent severe abdominal pain or allergic symptoms.
Explore Victoza Pen and Saxenda Pen. They contain liraglutide but have different indications and dose schedules. Read the existing Cureiva Related Cureiva readingsemaglutide product comparison for context. Links are educational, not substitution advice.
Review the Victoza official prescribing information and the leaflet supplied with the actual product. Local indications may differ.
Yes. Appropriate medical assessment, documentation and local prescribing regulations apply.
No. 6 mg/mL is the concentration in the liraglutide solution. Actual daily doses are set by a clinician.
Do not switch or combine products without clinical guidance because dosing, indications and risk profiles differ.
Manufacturer storage instructions may require refrigeration before first use and specific temperature limits afterward. Check the exact pack and shipping feasibility.
No. Availability depends on prescribing requirements, product authenticity checks, transport suitability and destination-country rules.
Victoza is generally injected once daily as prescribed. The injection time and prescribed dose should follow the product leaflet and clinician’s instructions.
No. Both contain liraglutide; do not combine them or substitute one for the other without prescriber guidance.
Follow the leaflet for the exact pen. U.S. labeling advises resuming the next scheduled dose; if more than three days have elapsed, contact your prescriber about restarting.
The risk can increase when used with insulin or sulfonylureas. Your clinician may adjust other diabetes medicines.
Get urgent medical attention for severe persistent abdominal pain, serious allergic symptoms or dehydration from ongoing vomiting or diarrhoea.
Cureiva Healthcare handles business and individual-patient product enquiries where permitted. This information is educational, is not a personal medical recommendation and does not claim individual physician review.
Reference check: October 2026.